论文部分内容阅读
自1989年11月以来,日本红十字血液中心除对乙型肝炎表面抗原(HBsAg)及表面抗体(HBsAb)进行筛除外,还作了高滴度(≥2~6)的乙型肝炎病毒核心抗体(HBcAb)筛除,HBcAb筛除目的是为了降低输血后乙肝(尤其是暴发型乙肝)的感染率。日本红十字非甲非乙型肝炎研究组报告,进行 HBcAb 筛除可以完全预防输血后乙肝。本文作者报道首例进行 HBcAb 筛除后发现的输血后暴发型乙肝。病例报告患者男性,70岁。因发热和黄疽于1991年9月19日入院。同年4月12日曾因肿瘤而行横结肠切除手术。手术时接受4名供血者共4U 血。9月初即发生肝病,并有轻度发热和尿色变化。
Since November 1989, Japan Red Cross Blood Center has made high-titer (≥2-6) hepatitis B virus nuclei in addition to screening for HBsAg and HBsAb Antibody (HBcAb) screening, HBcAb screening purpose is to reduce the transfusion of hepatitis B (especially fulminant hepatitis B) infection rate. Japan Red Cross Non-A Non-Hepatitis B Study Group reported that HBcAb screening can completely prevent hepatitis B after blood transfusion. The authors report the first case of posttransfusion fulminant hepatitis B found after screening for HBcAb. Case report Male patient, 70 years old. He was admitted to hospital on September 19, 1991 due to fever and jaundice. On April 12 the same year, he had a transverse colon resection due to cancer. Surgery to accept a total of 4 4U blood donor blood. Hepatic disease occurs in early September with mild fever and changes in urine color.